Lysosomal trapping of palbociclib and its functional implications

Area of Science:

• Oncology
• Cell Biology
• Pharmacology

Background:

• Palbociclib is a cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitor used in cancer therapy.
• Its primary action involves inducing cell cycle arrest and senescence in cancer cells.

Purpose of the Study:

• To investigate the intracellular localization and release mechanism of palbociclib.
• To uncover novel properties of palbociclib related to its drug accumulation in acidic vesicles.
• To explore the implications of lysosomal trapping for palbociclib's efficacy and therapeutic potential.

Main Methods:

• Observing palbociclib's intrinsic fluorescence within intracellular acidic vesicles.
• Assessing the effects of drug washout and extracellular medium dilution on palbociclib release.
• Evaluating the impact of lysosomotropic drugs (e.g., chloroquine) on palbociclib accumulation and cellular response.
• Comparing the behavior of palbociclib with other CDK4/6 inhibitors (ribociclib, abemaciclib).

Main Results:

• Palbociclib concentrates in intracellular acidic vesicles and is released upon dilution or washout.
• Short exposure to palbociclib induces stable cell-cycle arrest and long-term senescence.
• Palbociclib-treated cells release the drug, creating a paracrine senescence effect on susceptible cells, including resistant cancer cells.
• Lysosomotropic drugs reduce the required palbociclib dose for cell-cycle arrest and senescence.
• Ribociclib and abemaciclib exhibit similar lysosomal trapping behavior.

Conclusions:

• Lysosomal trapping explains the prolonged activity and paracrine effects of palbociclib.
• This mechanism offers potential for improved therapeutic dosing and efficacy of palbociclib.
• Lysosomal trapping is a common property among clinically approved CDK4/6 inhibitors.